INTRODUCTION: We tested the relationship between genotype, gene expression and suicidal behavior and major depressive disorder (MDD) in live subjects and postmortem samples for three genes, associated with the hypothalamic-pituitary-adrenal axis, suicidal behavior, and MDD; FK506-binding protein 5 (FKBP5), Spindle and kinetochore-associated protein 2 (SKA2), and Glucocorticoid Receptor (NR3C1). MATERIALS AND METHODS: Single-nucleotide polymorphisms (SNPs) and haplotypes were tested for association with suicidal behavior and MDD in a live (N = 277) and a postmortem sample (N = 209). RNA-seq was used to examine gene and isoform-level brain expression postmortem (Brodmann Area 9; N = 59). Expression quantitative trait loci (eQTL) relationships were examined using a public database (UK Brain Expression Consortium). RESULTS: We identified a haplotype within the FKBP5 gene, present in 47% of the live subjects, which was associated with increased risk of suicide attempt (OR = 1.58, t = 6.03, P = .014). Six SNPs on this gene, three SNPs on SKA2, and one near NR3C1 showed before-adjustment association with attempted suicide, and two SNPs of SKA2 with suicide death, but none stayed significant after adjustment for multiple testing. Only the SKA2 SNPs were related to expression in the prefrontal cortex (pFCTX). One NR3C1 transcript had lower expression in suicide relative to nonsuicide sudden death cases (b = -0.48, SE = 0.12, t = -4.02, adjusted P = .004). CONCLUSION: We have identified an association of FKBP5 haplotype with risk of suicide attempt and found an association between suicide and altered NR3C1 gene expression in the pFCTX. Our findings further implicate hypothalamic pituitary axis dysfunction in suicidal behavior.
INTRODUCTION: We tested the relationship between genotype, gene expression and suicidal behavior and major depressive disorder (MDD) in live subjects and postmortem samples for three genes, associated with the hypothalamic-pituitary-adrenal axis, suicidal behavior, and MDD; FK506-binding protein 5 (FKBP5), Spindle and kinetochore-associated protein 2 (SKA2), and Glucocorticoid Receptor (NR3C1). MATERIALS AND METHODS: Single-nucleotide polymorphisms (SNPs) and haplotypes were tested for association with suicidal behavior and MDD in a live (N = 277) and a postmortem sample (N = 209). RNA-seq was used to examine gene and isoform-level brain expression postmortem (Brodmann Area 9; N = 59). Expression quantitative trait loci (eQTL) relationships were examined using a public database (UK Brain Expression Consortium). RESULTS: We identified a haplotype within the FKBP5 gene, present in 47% of the live subjects, which was associated with increased risk of suicide attempt (OR = 1.58, t = 6.03, P = .014). Six SNPs on this gene, three SNPs on SKA2, and one near NR3C1 showed before-adjustment association with attempted suicide, and two SNPs of SKA2 with suicide death, but none stayed significant after adjustment for multiple testing. Only the SKA2 SNPs were related to expression in the prefrontal cortex (pFCTX). One NR3C1 transcript had lower expression in suicide relative to nonsuicide sudden death cases (b = -0.48, SE = 0.12, t = -4.02, adjusted P = .004). CONCLUSION: We have identified an association of FKBP5 haplotype with risk of suicide attempt and found an association between suicide and altered NR3C1 gene expression in the pFCTX. Our findings further implicate hypothalamic pituitary axis dysfunction in suicidal behavior.
Authors: J John Mann; Dianne Currier; Barbara Stanley; Maria A Oquendo; Lawrence V Amsel; Steven P Ellis Journal: Int J Neuropsychopharmacol Date: 2005-06-21 Impact factor: 5.176
Authors: Dirk van West; Filip Van Den Eede; Jurgen Del-Favero; Daniel Souery; Karl-Fredrik Norrback; Cornelia Van Duijn; Sam Sluijs; Rolf Adolfsson; Julien Mendlewicz; Dirk Deboutte; Christine Van Broeckhoven; Stephan Claes Journal: Neuropsychopharmacology Date: 2006-03 Impact factor: 7.853
Authors: Elisabeth F C van Rossum; Elisabeth B Binder; Matthias Majer; Jan W Koper; Marcus Ising; Sieglinde Modell; Daria Salyakina; Steven W J Lamberts; Florian Holsboer Journal: Biol Psychiatry Date: 2006-04-15 Impact factor: 13.382
Authors: Dhivya Arasappan; Simon B Eickhoff; Charles B Nemeroff; Hans A Hofmann; Mbemba Jabbi Journal: Mol Neurobiol Date: 2021-01-07 Impact factor: 5.590
Authors: Nadine M Melhem; Sara Munroe; Anna Marsland; Katarina Gray; David Brent; Giovanna Porta; Antoine Douaihy; Mark L Laudenslager; Frank DePietro; Rasim Diler; Henry Driscoll; Priya Gopalan Journal: Psychoneuroendocrinology Date: 2017-01-10 Impact factor: 4.905
Authors: Maura Boldrini; Hanga Galfalvy; Andrew J Dwork; Gorazd B Rosoklija; Iskra Trencevska-Ivanovska; Goran Pavlovski; René Hen; Victoria Arango; J John Mann Journal: Biol Psychiatry Date: 2019-01-17 Impact factor: 13.382
Authors: He Benny Chang; Sara Munroe; Katarina Gray; Giovanna Porta; Antoine Douaihy; Anna Marsland; David Brent; Nadine M Melhem Journal: J Affect Disord Date: 2018-09-07 Impact factor: 4.839
Authors: Marie E Breen; Sophia C Gaynor; Eric T Monson; Kelly de Klerk; Meredith G Parsons; Terry A Braun; Adam P DeLuca; Peter P Zandi; James B Potash; Virginia L Willour Journal: PLoS One Date: 2016-12-28 Impact factor: 3.240
Authors: Juan P Sanabria-Mazo; Carlos G Forero; Paula Cristobal-Narváez; Carlos Suso-Ribera; Azucena García-Palacios; Ariadna Colomer-Carbonell; Adrián Pérez-Aranda; Laura Andrés-Rodríguez; Lance M McCracken; Francesco D'Amico; Pere Estivill-Rodríguez; Bernat Carreras-Marcos; Antonio Montes-Pérez; Olga Comps-Vicente; Montserrat Esteve; Mar Grasa; Araceli Rosa; Antonio I Cuesta-Vargas; Michael Maes; Xavier Borràs; Silvia Edo; Antoni Sanz; Albert Feliu-Soler; Juan R Castaño-Asins; Juan V Luciano Journal: BMJ Open Date: 2020-07-23 Impact factor: 2.692